Never miss the latest news and offers - subscribe now!
Establishing a platform for developing and manufacturing therapeutic proteins that ensures predictable productivity and product quality will eliminate bottlenecks in tech transfer.
In this case study, Celltheon demonstrates a workflow using the Celltheon SMART Technology Platform in combination with the Allegro™ STR bioreactor range. The time from cDNA to RCB was reduced to less than 4 months while ensuring scalability between 3L to 200L pilot scale, with a pre-defined upstream and downstream processing platform for monoclonal antibodies and difficult to express proteins.
Participants will learn about:
Meet the authors from the ‘Insights on Successful Gene Therapy Manufacturing and Commercialization’ ebook
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Notice